Actinogen Medical Limited
Actinogen Medical Limited (ACW.AX) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Actinogen Medical Limited (ACW.AX), featuring income statements, balance sheets, and cash flow data.
Actinogen Medical Limited (ACW.AX) Income Statement & Financial Overview
Analyze Actinogen Medical Limited’s ACW.AX earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $9.02M | $909030.00 | $3.88M | $1.004M |
| Cost of Revenue | $0.00 | $211968.00 | $204553.00 | $201055.00 |
| Gross Profit | $9.02M | $697062.00 | $3.68M | $803045.00 |
| Gross Profit Ratio | $1.00 | $0.77 | $0.95 | $0.80 |
| R&D Expenses | $6.58M | $8.95M | $3.52M | $5.38M |
| SG&A Expenses | $3.84M | $3.40M | $3.67M | $2.90M |
| Operating Expenses | $10.42M | $12.35M | $7.18M | $8.28M |
| Total Costs & Expenses | $10.42M | $12.56M | $7.39M | $8.48M |
| Interest Income | $184247.00 | $106774.00 | $230742.00 | $135912.00 |
| Interest Expense | $13177.00 | $11115.00 | $6538.00 | $10061.00 |
| Depreciation & Amortization | $163188.00 | $211968.00 | $204553.00 | $201055.00 |
| EBITDA | -$1.44M | -$12.24M | -$6.99M | -$8.23M |
| EBITDA Ratio | -$0.16 | -$13.59 | -$1.85 | -$8.25 |
| Operating Income | -$1.40M | -$12.56M | -$7.39M | -$8.48M |
| Operating Income Ratio | -$0.15 | -$13.82 | -$1.90 | -$8.45 |
| Other Income/Expenses (Net) | -$9.11M | $96464.00 | $190818.00 | $42065.00 |
| Income Before Tax | -$10.51M | -$12.47M | -$7.20M | -$8.44M |
| Income Before Tax Ratio | -$1.16 | -$13.71 | -$1.85 | -$8.41 |
| Income Tax Expense | -$9.02M | -$909030.00 | -$3.88M | -$1.004M |
| Net Income | -$1.49M | -$11.56M | -$3.31M | -$7.44M |
| Net Income Ratio | -$0.16 | -$12.71 | -$0.85 | -$7.41 |
| EPS | -$0.001 | -$0.005 | -$0.002 | -$0.004 |
| Diluted EPS | -$0.001 | -$0.005 | -$0.002 | -$0.004 |
| Weighted Avg Shares Outstanding | $2.29B | $2.34B | $1.92B | $1.91B |
| Weighted Avg Shares Outstanding (Diluted) | $2.28B | $2.34B | $1.92B | $1.91B |
The company's financials show resilient growth, with revenue advancing from $1.004M in Q2 2023 to $9.02M in Q4 2024. Gross profit remained healthy with margins at 100% in Q4 2024 compared to 80% in Q2 2023. Operating income hit -$1.40M last quarter, sustaining a consistent -15% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$1.44M. Net income rose to -$1.49M, while earnings per share reached -$0.001. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan